PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now? Yahoo Finance
Covered in this story
What has happened since
- Pfizer is down 4.1% since this was published, 41 days ago.
- Bristol Myers Squibb is down 13.4% since this was published, 41 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pfizer
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 48 stories mentioning Pfizer, the earliest published 22 May 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.